DEVA:IST
Deva Holding AS
TRY 78.10
arrow_downward
-1.39%(-1.10) 1D
Okt 15, 6:10:00 PM GMT+3 · TRY
search
Lahat ng simbolo
| Simbolo | Presyo | Palitan | % ng Pagbabago |
|---|
insights_autoBumubuo ng mga nangungunang insight para sa DEVA...
Buksan
TRY 78.10
Mataas
TRY 79.10
Mababa
TRY 77.05
Mkt. cap
15.62B
Avg. na dami
613.11K
Dami
245.82K
Mataas nang 52-wk
TRY 109.30
Mababa nang 52-wk
TRY 57.50
EPS
-TRY 4.21
Mga natitirang share
200.02M
Bilang ng mga empleyado
3K
Buksan
TRY 78.10
Mataas
TRY 79.10
Mababa
TRY 77.05
Mkt. cap
15.62B
Avg. na dami
613.11K
Dami
245.82K
Mataas nang 52-wk
TRY 109.30
Mababa nang 52-wk
TRY 57.50
EPS
-TRY 4.21
Mga natitirang share
200.02M
Bilang ng mga empleyado
3K
Mga balita at kwento
Mula sa mga source sa web at partner sa balita
FXStreet
·
9 oras ang nakalipas
Dow Jones futures gains ahead of US PPI, Retail Sales data
Bloomberg.com
·
3 araw ang nakalipas
S&P 500 Wavers as Earnings Bets Offset Chip Rout: Markets Wrap
MarketWatch
·
1 buwan ang nakalipas
The S&P 500 keeps climbing on days when stocks broadly struggle. Here’s what’s going on.
Reuters
·
1 buwan ang nakalipas
S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
Profile
DEVA Holding A.Ş. is a Turkish pharmaceutical company operating since 1958. Its principal activities include the development, manufacture and marketing of human pharmaceuticals and active pharmaceutical ingredients. The company also operates in veterinary medicines, cologne, medical ampoules and food supplements.
A majority stake in the company was acquired by EastPharma in 2006. DEVA Holding is listed on Borsa Istanbul, and its chairman and chief executive officer is Philipp Haas.
As of 2025, the company had more than 675 products across 15 therapeutic areas. According to IQVIA data cited in its annual report, DEVA ranked third in the Turkish pharmaceutical market by unit sales in 2025, with a market share of 4.5%. Wikipedia
Tungkol sa Deva Holding AS